These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32267995)

  • 1. Insulin and heparin challenge tests are useful for choosing an optimal insulin regimen in a case of subcutaneous insulin resistance.
    Nakamura Y; Nagao M; Kobayashi S; Oba T; Shuto Y; Fukuda I; Oikawa S; Sugihara H
    J Diabetes Investig; 2020 Sep; 11(5):1370-1373. PubMed ID: 32267995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A patient with subcutaneous-insulin resistance treated by insulin lispro plus heparin.
    Tokuyama Y; Nozaki O; Kanatsuka A
    Diabetes Res Clin Pract; 2001 Dec; 54(3):209-12. PubMed ID: 11689276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case of subcutaneous insulin resistance syndrome treated with ultra-rapid insulin lispro.
    Ishii T; Katayama A; Sue M; Kuribayashi R; Tenta M; Matsushita Y; Takeda M; Iseda I; Tani S; Hida K
    J Diabetes Investig; 2022 Mar; 13(3):588-591. PubMed ID: 34510782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H; Melki V; Bessières-Lacombe S; Tauber JP
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
    Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Subcutaneous Regular Insulin and Lispro Insulin in Diabetics Receiving Continuous Nutrition: A Numerical Study.
    Stull MC; Strilka RJ; Clemens MS; Armen SB
    J Diabetes Sci Technol; 2015 Jun; 10(1):137-44. PubMed ID: 26134836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
    [No Abstract]   [Full Text] [Related]  

  • 10. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion.
    Liebl A; Hoogma R; Renard E; Geelhoed-Duijvestijn PH; Klein E; Diglas J; Kessler L; Melki V; Diem P; Brun JM; Schaepelynck-Bélicar P; Frei T;
    Diabetes Obes Metab; 2009 Nov; 11(11):1001-8. PubMed ID: 19740082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes.
    Parkner T; Laursen T; Vestergaard ET; Hartvig H; Smedegaard JS; Lauritzen T; Christiansen JS
    Diabet Med; 2008 May; 25(5):585-91. PubMed ID: 18445172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.
    Launay B; Zinman B; Tildesley HD; Strack T; Chiasson JL
    Diabetes Care; 1998 Oct; 21(10):1627-31. PubMed ID: 9773721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.
    Thrasher J; Surks H; Nowotny I; Pierre S; Rotthaeuser B; Wernicke-Panten K; Garg S
    J Diabetes Sci Technol; 2018 May; 12(3):680-686. PubMed ID: 29359575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
    Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
    Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study.
    Bode BW; Garg SK; Norwood P; Morales C; Hardy T; Liu R; Ignaut D
    Diabetes Technol Ther; 2021 Jan; 23(1):41-50. PubMed ID: 32640842
    [No Abstract]   [Full Text] [Related]  

  • 17. Insulin Bolus Administration in Insulin Pump Therapy: Effect of Bolus Delivery Speed on Insulin Absorption from Subcutaneous Tissue.
    Regittnig W; Urschitz M; Lehki B; Wolf M; Kojzar H; Mader JK; Ellmerer M; Pieber TR
    Diabetes Technol Ther; 2019 Jan; 21(1):44-50. PubMed ID: 30620643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe insulin resistance treated with insulin lispro.
    Gill G; Williams G
    Lancet; 1997 Jan; 349(9046):211. PubMed ID: 9111571
    [No Abstract]   [Full Text] [Related]  

  • 19. Glycemic control and perinatal outcomes of pregnancies complicated by type 1 diabetes: influence of continuous subcutaneous insulin infusion and lispro insulin.
    Chico A; Saigi I; García-Patterson A; Santos MD; Adelantado JM; Ginovart G; de Leiva A; Corcoy R
    Diabetes Technol Ther; 2010 Dec; 12(12):937-45. PubMed ID: 21128840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.
    McVey E; Hirsch L; Sutter DE; Kapitza C; Dellweg S; Clair J; Rebrin K; Judge K; Pettis RJ
    J Diabetes Sci Technol; 2012 Jul; 6(4):743-54. PubMed ID: 22920798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.